Recruiting

Avera Cancer Sequencing and Analytics Protocol (ASAP)

ClinicalTrials.gov IDNCT05142033

PhaseNot Applicable

Enrollment25000

SponsorAvera McKennan Hospital & University Health Center

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer, Lung Cancer, Colon Cancer, GI Cancer, Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, CNS Cancer, Hematologic Cancer

About this study

The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types. Comprehensive molecular profiling will include somatic tumor testing (tissue and/or blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and/or whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples. To maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research. Data collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.

Primary outcomes

Percent of patients participating in comprehensive molecular profiling (5 years)
Percent of patients referred for cascade genetic testing (5 years)
Percent of patients referred for molecularly targeted clinical trials (5 years)

Eligibility information

Inclusion Criteria: * Must be at least 18 years of age * Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer * Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation Exclusion Criteria: * Participants incapable of understanding the items listed in the consent form and process * Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements

Study locations

Avera Cancer Institute - Marshall, Marshall, Minnesota 56258 United States
Avera Cancer Institute - Aberdeen, Aberdeen, South Dakota 57401 United States
Avera Cancer Institute - Mitchell, Mitchell, South Dakota 57301 United States
Avera Cancer Institute - Pierre, Pierre, South Dakota 57501 United States
Avera Cancer Institute, Sioux Falls, South Dakota 57105 United States
Avera Cancer Institute - Yankton, Yankton, South Dakota 57078 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.